Publications by authors named "S N Salmasi"

Vermillion lip squamous cell carcinoma (SCC) is a rare cancer, currently grouped together with the cutaneous lip under the cutaneous squamous cell carcinoma (cSCC) system. Herein, we present a case of an 81-year-old male with locally advanced lower lip SCC involving the vermillion who achieved a complete pathologic response to neoadjuvant cetuximab after the failure of the programed cell death protein-1 (PD-1) inhibitor, cemiplimab. He was followed with clinical observation, with special attention to skin/mucosal surfaces.

View Article and Find Full Text PDF

MicroRNAs (miRNAs) are a type of specific molecules that control the activities of the uterus, such as the process of cellular maturing and evolution. A lot of substances like growth factors, cytokines, and transcription factors play a role in embryo-endometrial interaction. MiRNAs could regulate various these factors by attaching to the 3' UTR of their mRNAs.

View Article and Find Full Text PDF

Aim: This article provides an overview of time-to-event (TTE) analysis in pharmacoepidemiology.

Materials & Methods: The key concept of censoring is reviewed, including right-, left-, interval- and informative censoring. Simple descriptive statistics are explained, including the nonparametric estimation of the TTE distribution as per Kaplan-Meier method, as well as more complex TTE regression approaches, including the parametric Accelerated Failure Time (AFT) model and the semi-parametric Cox Proportional Hazards and Restricted Mean Survival Time (RMST) models.

View Article and Find Full Text PDF
Article Synopsis
  • 5-azacitidine is a treatment for myelodysplastic syndrome (MDS) and certain myeloproliferative neoplasms (MPNs), but it can cause side effects like myelosuppression and nausea, with rare, serious allergic reactions.
  • A case study describes a 71-year-old man with MDS/MPN who experienced repeated episodes of angioedema after starting 5-azacitidine, affecting various body areas and deemed causally linked to the medication.
  • After discontinuing 5-azacitidine due to ongoing angioedema, the patient responded well to steroids and is now managing his blood condition with low-dose hydroxyurea, while the exact cause
View Article and Find Full Text PDF
Article Synopsis
  • * A case study details a 77-year-old woman with essential thrombocytosis who, after 20 weeks on low-dose hydroxyurea, experienced an unexpected change in hair color from gray to dark brown, along with other skin changes.
  • * The patient's side effect was monitored without intervention since she was pleased with the new hair color, suggesting that hydroxyurea may have both therapeutic benefits and unexpected aesthetic effects due to melanocyte activation.
View Article and Find Full Text PDF